Ajjai Shivaram Alva, MBBS, discusses the shift toward combination therapy versus monotherapy in metastatic renal cell carcinoma.
Ajjai Shivaram Alva, MBBS
Advertisement
Articles by Ajjai Shivaram Alva, MBBS
Ajjai Shivaram Alva, MBBS, discusses the results of the CABOSUN trial in renal cell carcinoma.
Ajjai Shivaram Alva, MBBS, discusses TKI monotherapy and in combination with immunotherapy for patients with renal cell carcinoma.
Ajjai Shivaram Alva, MBBS, discusses class-specific toxicities of TKIs in renal cell carcinoma.
Advertisement
Latest Updated Articles
Dr. Alva on the Toxicity Profiles of TKIs in RCCJanuary 6th 2020
Dr. Alva on TKI Monotherapy and Combinations for RCCJanuary 21st 2020
Dr. Alva on Results of the CABOSUN Trial in RCCFebruary 3rd 2020
Dr. Alva on the Shift Toward Combination Therapy in mRCCFebruary 14th 2020
Advertisement
Advertisement
Trending on OncLive
1
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
2
The OncFive: Top Oncology Articles for the Week of 5/31
3
From Toilet Cleaner to Thoracic Oncologist and Patient: How Ross Camidge Built a Life Worth Loving
4
Breast Cancer Experts Spotlight Practice-Informing and Thought-Provoking Data From ASCO 2026
5